Clinical trials: Connective Tissue Defect
- Condition Connective Tissue Defect
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Cartilage Diseases
Non-Interventional Study to Evaluate Safety and Efficacy of NOVOCART 3D in Patients With Cartilage Defects
Non-interventional study to evaluate safety and efficacy of NOVOCART 3D in adult and adolescent patients with full thickness cartilage defects after the treatment with NOVOCART 3D.
- Trial name
- NISANIK (NCT02348697)
- Testing
- NOVOCART 3D
- Where
- 9 sites in Germany
- Volunteers
- 81 people
- Sponsor
- Tetec AG
Cartilage Disease
Non-interventional Study With NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients
Prospective, multicenter, single-arm non-interventional study to evaluate the efficacy, safety and health economics of NOVOCART 3D in the Treatment fo cartilage defects of the knee in pediatric patients wieh closed epiphyseal…
- Trial name
- JUNOVO (NCT04186208)
- Testing
- NOVOCART 3D
- Where
- 6 sites in Germany
- Volunteers
- 42 people
- Sponsor
- Tetec AG
Chondral Defect, Articular Cartilage Defect
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with…
- Trial name
- MASCOT (NCT06915233)
- Testing
- autologous cultured chondrocytes on porcine collagen membrane, Bone Marrow Stimulation
- Where
- 9 sites in United States
- Volunteers
- 309 people
- Sponsor
- Vericel Corporation
Cartilage Disease
Non-interventional Study With NOVOCART® Inject in the Reconstruction of the Knee Cartilage Defects
Retrospective non-interventional study to evaluate safety and efficacy of NOVOCART® Inject in patients with full-thickness cartilage defects in the knee joint.
- Trial name
- RENOVO (NCT02941120)
- Where
- 7 sites in Germany
- Volunteers
- 245 people
- Sponsor
- Tetec AG
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Cartilage Disease
Non-interventional Study in Pediatric Patients Treated With NOVOCART Inject in the Knee
The study is a prospective, multicenter, single-arm non-interventional study to evaluate the efficacy, safety and health economics of NOVOCART® Inject in the treatment of cartilage defects of the knee in pediatric patients with…
- Trial name
- NINJA (NCT05391841)
- Testing
- NOVOCART Inject
- Where
- 6 sites in Germany
- Sponsor
- Tetec AG